New Formulation Offers Another Treatment Option of Noxafil for Critically Ill Patients
MSD (Merck Sharp & Dohme Limited) announced the UK launch of Noxafil (posaconazole), 300 mg concentrate for solution for intravenous infusion (IV), which offers another option to treat fungal infections in critically ill patients who are unable to take oral versions. This follows the European Commission approval granted on 18 September 2014.
Posaconazole now offers the benefit of being available in a range of formulations, to suit the needs of various clinical situations and different types of patients. Following the completion of the IV clinical development programme, where the pharmacokinetic and safety data was bridged to the existing data (including efficacy data) from the oral suspension studies, posaconazole is now available as concentrate for solution for infusion with a once-daily dosing regimen after a twice-daily loading dose on day one.
“The availability of the IV infusion allows clinicians to start posaconazole, knowing they can continue treatment as patients’ clinical needs change by switching between formulations according to dosing recommendations,” commented Professor Graham Jackson, Haematology Department, Royal Victoria Infirmary, Newcastle.
The marketing authorisation for posaconazole concentrate for solution for infusion was supported by the results of a non-comparative multi-centre study performed to evaluate the pharmacokinetic properties, safety and tolerability of posaconazole concentrate for solution for infusion.
“Posaconazole concentrate for solution for infusion now offers another treatment option for clinicians when treating critically ill patients and where the oral tablet or oral suspension are less suitable.” said Paul Lamba, Director of Medical Affairs at MSD UK. “We are pleased to be able to add the new intravenous posaconazole formulation to our portfolio of medicines for infectious diseases in the hospital and clinic.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance